SCHEMBL10195600

SCHEMBL10195600

Cc1ccc(-c2cnn(CCO)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.49
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
KIT P10721 1/20 0.46
LRRK2 Q5S007 1/20 0.46
PDK2 Q15119 6/20 0.45
PDK1 Q15118 1/20 0.45
PDK3 Q15120 1/20 0.45
KDR P35968 1/20 0.45
EPHB4 P54760 1/20 0.45
TEK Q02763 1/20 0.45
MAP4K4 O95819 1/20 0.44
KCNH2 Q12809 6/20 0.44
GRIN2B Q13224 2/20 0.43
BRD4 O60885 1/20 0.42
CREBBP Q92793 1/20 0.42
PIK3CA P42336 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13036117 0.84 PIK3CD (0.51) NAMPTPRMT5WDR77LRRK2KDR
SCHEMBL21601373 0.83 LRRK2 (0.46) LRRK2KDREPHB4TEKKCNH2
SCHEMBL11826508 0.82 L3MBTL1 (0.61) NAMPTPRMT5WDR77KITPDK2
SCHEMBL11827587 0.82 MEN1 (0.58) NAMPTPRMT5WDR77KITPDK2
SCHEMBL15317750 0.82 NAMPT (0.46) NAMPTPRMT5WDR77KITPDK2
SCHEMBL17809809 0.80 LRRK2 (0.64) PRMT5WDR77LRRK2KDREPHB4
SCHEMBL17809806 0.80 CREBBP (0.44) NAMPTLRRK2KDREPHB4TEK
SCHEMBL17809804 0.80 TGFBR1 (0.53) LRRK2KDREPHB4TEKMAP4K4
SCHEMBL22918695 0.80 PRMT5 (0.53) NAMPTPRMT5WDR77KITPDK2
SCHEMBL2082437 0.80 NAMPT (0.52) NAMPTPRMT5WDR77LRRK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023069884-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2023-04-27 WO disclosed
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
EP-2655357-B1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO SA (CH) 2016-06-22 EP disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed
WO-2012084704-A1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO S.A. (CH) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 NAMPT 937/4885PRMT5 282/4885WDR77 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.